Press Releases

The State of the Drug Discovery Nation unveiled as new report provides vital insights for the development of new medicines

The Medicines Discovery Catapult and BioIndustry Association call on the R&D community to address five themes to help boost productivity

BIA welcomes the release of the AMR Industry Alliance’s first progress report

The BIA today welcomes the release of the AMR Industry Alliance’s first progress report assessing the action being taken to tackle antimicrobial resistance.

BIA responds to MHRA update on Brexit preparations

The BIA has today responded to an update from the Medicines and Healthcare products Regulatory Agency (MHRA) to pharmaceutical companies on preparations for exiting the European Union.

BIA intervenes in Supreme Court case of critical importance to the bioscience sector

The UK Bioindustry Association (BIA) has been granted permission by the Supreme Court to intervene in its review of Warner-Lambert Company LLC v Generics (UK) Ltd and Actavis. The review will examine the issue of “plausibility” in patent law and could potentially impact the amount of data and evidence required before an invention can be patented. The BIA has intervened in the case to highlight the importance of the issue to the UK’s bioscience sector.

 

Member News

Domainex wins award to develop GPCR drug discovery technology

Domainex Ltd, a privately-owned drug discovery services company, has been awarded £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs). This investment represents a significant opportunity for the company to develop a technology to accelerate the discovery of new drugs.

CGT Catapult announces viral vector manufacturing technology collaboration with Freeline Therapeutics

Freeline will develop a ‘next-generation’ therapy platform at CGT Catapult’s UK-based large-scale GMP manufacturing centre. The company will further develop proprietary viral vector manufacturing technology for bleeding and other disorders.

Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands

Repligen Corporation (NASDAQ:RGEN) announces its extended long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen's facilities in Waltham, MA and Lund, Sweden.

Medherant wins Excellence in Science & Technology Award

Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.

 

BIA blog

CEO Update: Monday 22 January

On Thursday we released our joint report with the Medicines Discovery Catapult ‘State of the Discovery Nation 2018’. Launched by Sir Mark Walport at Alderley Park, the report is based on surveys and over 100 in-depth interviews with senior executives of UK drug discovery companies and shows that global R&D productivity is under unprecedented pressure. The BIA, along with the Medicines Discovery Catapult, is committed to working with others to create long-term solutions to these issues, which will drive productivity and further success in the important years ahead.

Tackling antibiotic resistance: AMR Industry Alliance's progress report launch event

On Friday 12 January 2018, the Alliance held a launch event for their first, highly anticipated progress report at Chatham House in London. BIA CEO and Vice-Chair of the International Confederation of Biotech Associations (ICBA), Steve Bates, was invited to speak as part of an expert and media roundtable briefing, alongside other global leaders in this fight. In this blog, we take a brief look at what they discussed, and some of the key take-home messages from the report.

The BIA at JP Morgan week and Biotech Showcase 2018

The JP Morgan week at the start of the year was a must attend event for many investors and CEOs from small biotechs to large pharma in the Life Sciences sector. For four days in early January San Francisco became a focus for life science entrepreneurs, as the annual JP Morgan Healthcare Conference and Biotech Showcase came to town. This was an important opportunity to collaborate, partner and seek investment from a huge range of companies from around the world.

CEO Update: Monday 15 January

I had a productive few days in San Francisco at the JP Morgan and Biotech Showcase events last week. Alongside Genomics England and MedCity, the BIA co-sponsored a panel discussion ‘Generation Genome and Industrial Strategy: Leveraging UK Leadership in Genomics’. Representatives from Genomics England, technology partners, SMEs and the venture community all contributed to a very insightful and fascinating debate the opportunities and challenges that will shape the growth of the UK’s genomics industry and its impact worldwide.

 

Our publications

Influencing and shaping our sector, BIA update: July – October 2017

his quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from July to October 2017. Brexit, the government’s Industrial Strategy and a potential sector deal have been keeping all of us at the BIA very busy this quarter.

Growing the next generation of UK management talent

BIA directory of industry training opportunities to help build the next generation of management talent.

A vision for the UK life sciences sector in 2025

This vision, developed in consultation with the BIA Board and sector experts, sets out an ambitious goal for the UK to become a top global cluster in life sciences by 2025.